Evidence map›Paper›PMID 23448518›Full record

ArticleEpigenetics & chromatin2013

Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression.

Adrienne Grzenda, Gwen Lomberk, Phyllis Svingen, Angela Mathison, Ezequiel Calvo, Juan Iovanna, Yuning Xiong, William Faubion, Raul Urrutia

Open access · goldAbstract read
In one paragraph

Article in Epigenetics & chromatin, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Regulatory roles of alternative splicing at Ezh2 gene in mouse oocytes.Reproductive biology and endocrinology : RB&E · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  14. Review
  15. Connecting the dots: chromatin and alternative splicing in EMT.Biochemistry and cell biology = Biochimie et biologie cellulaire · 2016
    Review
  16. Article
  17. Review
  18. EZH2 in Bladder Cancer, a Promising Therapeutic Target.International journal of molecular sciences · 2015
    Review
  19. Review
  20. EZH2 modulates angiogenesis in vitro and in a mouse model of limb ischemia.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Adrienne GrzendaLaboratory of Epigenetics and Chromatin Dynamics, Mayo Clinic, Rochester, MN, 55905, USA. urrutia.raul@mayo.edu.
Gwen Lomberk
Phyllis Svingen
Angela Mathison
Ezequiel Calvo
Juan Iovanna
Yuning Xiong
William Faubion
Raul Urrutia
Mayo Clinic · USInserm · FR

Funding

ZINC FINGER GENES AND PANCREATIC CELL GROWTHR01DK052913 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI LOMBERK, GWEN, URRUTIA, RAUL A. · 1998 to 2023
$7.0M
KLF10 regulates colitis through mediating TGFb induction of FOXP3 in Treg cells.R01AI089714 · NIAID · MAYO CLINIC ROCHESTER · PI FAUBION, WILLIAM A · 2011 to 2025
$6.3M
Tumor Microenvironment/Angiogenesis Training GrantT32CA148073 · NCI · MAYO CLINIC ROCHESTER · PI MC NIVEN, MARK A. · 2010 to 2014
$1.2M
NCI NIH HHS T32 CA148073NIAID NIH HHS R01 AI089714NIDDK NIH HHS R01 DK052913
6 · The paper itself

Abstract

backgroundHistone methyltransferase enhancer of zeste homologue 2 (EZH2) forms an obligate repressive complex with suppressor of zeste 12 and embryonic ectoderm development, which is thought, along with EZH1, to be primarily responsible for mediating Polycomb-dependent gene silencing. Polycomb-mediated repression influences gene expression across the entire gamut of biological processes, including development, differentiation and cellular proliferation. Deregulation of EZH2 expression is implicated in numerous complex human diseases. To date, most EZH2-mediated function has been primarily ascribed to a single protein product of the EZH2 locus.

resultsWe report that the EZH2 locus undergoes alternative splicing to yield at least two structurally and functionally distinct EZH2 methyltransferases. The longest protein encoded by this locus is the conventional enzyme, which we refer to as EZH2α, whereas EZH2β, characterized here, represents a novel isoform. We find that EZH2β localizes to the cell nucleus, complexes with embryonic ectoderm development and suppressor of zeste 12, trimethylates histone 3 at lysine 27, and mediates silencing of target promoters. At the cell biological level, we find that increased EZH2β induces cell proliferation, demonstrating that this protein is functional in the regulation of processes previously attributed to EZH2α. Biochemically, through the use of genome-wide expression profiling, we demonstrate that EZH2β governs a pattern of gene repression that is often ontologically redundant from that of EZH2α, but also divergent for a wide variety of specific target genes.

conclusionsCombined, these results demonstrate that an expanded repertoire of EZH2 writers can modulate histone code instruction during histone 3 lysine 27-mediated gene silencing. These data support the notion that the regulation of EZH2-mediated gene silencing is more complex than previously anticipated and should guide the design and interpretation of future studies aimed at understanding the biochemical and biological roles of this important family of epigenomic regulators.

Identifiers

PMID23448518
PMCPMC3606351
OpenAlexW2126449122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.